Prospective Grant of Start-Up Exclusive License: Therapeutics for Frontotemporal Dementia, Alzheimer's Disease Excluding Intranasal Delivery, Neuronal Injury (Stroke, Traumatic Brain Injury (TBI) and Epilepsy), and Progressive Supranuclear Palsy, 65662-65663 [2016-22897]
Download as PDF
<![CDATA[
65662
Federal Register / Vol. 81, No. 185 / Friday, September 23, 2016 / Notices
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Rapid Assessment of Zika
Virus (ZIKV) Complications (R21).
Date: October 18–19, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Raymond R. Schleef,
Ph.D., Senior Scientific Review, Officer
Scientific Review Program, Division of
Extramural Activities, Room 3E61, National
Institutes of Health/NIAID, 5601 Fishers
Lane, MSC 9823, Bethesda, MD 20892–9823,
(240) 669–5019, schleefrr@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 19, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–22899 Filed 9–22–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed
Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; NEI Clinical and
Epidemiological grant applications
(Cooperative Agreements and RPGs).
Date: October 19, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
VerDate Sep<11>2014
18:22 Sep 22, 2016
Jkt 238001
Contact Person: Jeanette M. Hosseini,
Ph.D., Scientific Review Officer, 5635 Fishers
Lane, Suite 1300, Bethesda, MD 20892, 301–
451–2020, jeanetteh@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: September 19, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–22898 Filed 9–22–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of SCORE Applications.
Date: October 27–28, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The St. Regis, Washington DC, 923
16th and K Street NW., Washington, DC
20006.
Contact Person: John J. Laffan, Scientific
Review Officer, Office of Scientific Review,
National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18J, Bethesda,
MD 20892, 301–594–2773,
laffanjo@mail.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of MIRA Applications.
Date: November 3–4, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn DC/Bethesda,
7301 Waverly Street, Bethesda, MD 20814.
Contact Person: Saraswathy Seetharam,
Ph.D., Scientific Review Officer, Office
Scientific Review, National Institute of
General Medical Sciences, National Institutes
Health, 45 Center Drive, Room 3AN12C,
Bethesda, MD 20892, 301–594–2763,
seetharams@nigms.nih.gov.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research; Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
Dated: September 19, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–22900 Filed 9–22–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive License: Therapeutics for
Frontotemporal Dementia, Alzheimer’s
Disease Excluding Intranasal Delivery,
Neuronal Injury (Stroke, Traumatic
Brain Injury (TBI) and Epilepsy), and
Progressive Supranuclear Palsy
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institute of
Neurological Disorders and Stroke
(NINDS), National Institutes of Health
(NIH), Department of Health and Human
Services, is contemplating the grant of a
start-up exclusive license to Cogentis
Therapeutics, Inc. which is located in
Maryland, to practice the inventions
embodied in the following patents: U.S.
Patent 8,597,660, issued December 3,
2013 (HHS reference E–144–2010/0–
US–02).
The patent rights in these inventions
have been assigned to the United States
of America. The prospective start-up
exclusive license territory may be
worldwide and the field of use may be
limited to Frontotemporal dementia,
Alzheimer’s disease excluding
intranasal delivery, Neuronal injury
(stroke, traumatic brain injury (TBI) and
epilepsy), and Progressive Supranuclear
Palsy.
DATES: Only written comments and/or
applications for a license which are
received by NINDS Technology Transfer
on or before October 11, 2016 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated start-up exclusive license
SUMMARY:
E:\FR\FM\23SEN1.SGM
23SEN1
Federal Register / Vol. 81, No. 185 / Friday, September 23, 2016 / Notices
should be directed to: Susan Ano, Ph.D.,
NINDS Technology Transfer, 31 Center
Drive, Suite 8A52, MS2540, Bethesda,
MD 20892; Telephone: (301) 435–5515;
Email: anos@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2016–22897 Filed 9–22–16; 8:45 am]
This
sradovich on DSK3GMQ082PROD with NOTICES
invention discloses treating
neurodegenerative diseases by
administering cyclin dependent kinase
5 (Cdk5) inhibitory peptides derived
from P35, the activator of Cdk5.
Abnormally hyperactive Cdk5 has been
shown to be associated with a variety of
neurodegenerative disorders. This
invention describes isolated peptide
fragments, pharmaceutical compositions
and methods for use of such for treating
subjects with a neurodegenerative
disease, such as Alzheimer’s disease
(AD), Amyotrophic Lateral Sclerosis
(ALS) and Parkinson’s disease (PD). An
inhibitory fragment, TFP5, disclosed in
this invention, has been shown to
ameliorate symptoms of AD in disease
animal models without any evidence of
toxicity. In particular, TFP5 treatment of
rat cortical neurons reduced
hyperactivation of Cdk5 upon neuronal
stress and insults. Following
intraperitoneal (ip) injection, TFP5 was
capable of crossing the blood-brain
barrier and localizing within the brain
where it was found to rescue memory
deficits and pathology in a double
transgenic mouse (APP/PS1) AD model.
The prospective start-up exclusive
license may be granted unless within
fifteen (15) days from the date of this
published notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated start-up
exclusive license. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
VerDate Sep<11>2014
18:22 Sep 22, 2016
Jkt 238001
Dated: September 19, 2016.
Susan Ano,
Technology Development Coordinator,
NINDS Technology Transfer, National
Institutes of Health.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Palliative Care:
Conversations Matter® Phase Two
Evaluation (National Institute of
Nursing Research)
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below. This proposed
information collection was previously
published in the Federal Register on
July 12, 2016, page 45169 (81 FR 45169)
and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to (202) 395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Ms. Diana
Finegold, Office of Communications and
Public Liaison, NINR, NIH, Building 31,
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
65663
Suite 5B03, 31 Center Drive, Bethesda,
MD 20892, or call non-toll-free number
(301) 496–0209, or Email your request,
including your address to:
Diana.Finegold@nih.gov.
SUPPLEMENTARY INFORMATION: The
National Institute of Nursing Research
(NINR), National Institutes of Health,
may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: Palliative Care:
Conversations Matter® Phase Two
Evaluation, 0925–0683, National
Institute of Nursing Research (NINR),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The NINR Palliative Care:
Conversations Matter® initiative, which
launched in FY 2014, is now in its
second phase. The first phase was
focused on providing materials and
tools to assist health care providers in
having sometimes difficult
conversations with children and
families about palliative care. The
second phase of the campaign, launched
in FY 2015, focuses on children,
parents, and families. The Palliative
Care: Conversations Matter® Phase Two
evaluation will assess the information
and materials being disseminated to
children, parents, and families. Survey
findings will help (1) determine if the
campaign is effective, relevant, and
useful to the families and caregivers of
children living with serious illnesses;
(2) to better understand the information
needs of families and caregivers to
inform future campaign efforts; and (3)
examine how effective the campaign
materials are in providing families and
caregivers with information on
palliative care.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
371 hours.
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 81, Number 185 (Friday, September 23, 2016)]
[Notices]
[Pages 65662-65663]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-22897]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive License: Therapeutics for
Frontotemporal Dementia, Alzheimer's Disease Excluding Intranasal
Delivery, Neuronal Injury (Stroke, Traumatic Brain Injury (TBI) and
Epilepsy), and Progressive Supranuclear Palsy
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institute of Neurological Disorders and
Stroke (NINDS), National Institutes of Health (NIH), Department of
Health and Human Services, is contemplating the grant of a start-up
exclusive license to Cogentis Therapeutics, Inc. which is located in
Maryland, to practice the inventions embodied in the following patents:
U.S. Patent 8,597,660, issued December 3, 2013 (HHS reference E-144-
2010/0-US-02).
The patent rights in these inventions have been assigned to the
United States of America. The prospective start-up exclusive license
territory may be worldwide and the field of use may be limited to
Frontotemporal dementia, Alzheimer's disease excluding intranasal
delivery, Neuronal injury (stroke, traumatic brain injury (TBI) and
epilepsy), and Progressive Supranuclear Palsy.
DATES: Only written comments and/or applications for a license which
are received by NINDS Technology Transfer on or before October 11, 2016
will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated start-up
exclusive license
[[Page 65663]]
should be directed to: Susan Ano, Ph.D., NINDS Technology Transfer, 31
Center Drive, Suite 8A52, MS2540, Bethesda, MD 20892; Telephone: (301)
435-5515; Email: anos@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This invention discloses treating
neurodegenerative diseases by administering cyclin dependent kinase 5
(Cdk5) inhibitory peptides derived from P35, the activator of Cdk5.
Abnormally hyperactive Cdk5 has been shown to be associated with a
variety of neurodegenerative disorders. This invention describes
isolated peptide fragments, pharmaceutical compositions and methods for
use of such for treating subjects with a neurodegenerative disease,
such as Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS)
and Parkinson's disease (PD). An inhibitory fragment, TFP5, disclosed
in this invention, has been shown to ameliorate symptoms of AD in
disease animal models without any evidence of toxicity. In particular,
TFP5 treatment of rat cortical neurons reduced hyperactivation of Cdk5
upon neuronal stress and insults. Following intraperitoneal (ip)
injection, TFP5 was capable of crossing the blood-brain barrier and
localizing within the brain where it was found to rescue memory
deficits and pathology in a double transgenic mouse (APP/PS1) AD model.
The prospective start-up exclusive license may be granted unless
within fifteen (15) days from the date of this published notice, the
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated start-up exclusive license. Comments and objections
submitted to this notice will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: September 19, 2016.
Susan Ano,
Technology Development Coordinator, NINDS Technology Transfer, National
Institutes of Health.
[FR Doc. 2016-22897 Filed 9-22-16; 8:45 am]
BILLING CODE 4140-01-P
